After clicking on a story, use the back arrow in your browser to return to your search results. Use phrases "in quotes" or the tools below to better filter your results.
The deal adds promising drug candidates to Merck’s oncology portfolio, as its bestselling cancer therapy Keytruda will see its patent expire later this decade.